| Dr Andrew Wall, MD | |
|
1 Medical Center Dr, Morgantown, WV 26506-1200 | |
| (304) 293-7215 | |
| (304) 293-6702 |
| Full Name | Dr Andrew Wall |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 1 Medical Center Dr, Morgantown, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164963492 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 323039 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospital & Clinics | Lafayette, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Congress Emergency Group Llc | 1557580354 | 8 |
News Archive
A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells.
Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project' consortium to develop a vaccine against Staphylococcus aureus (S. aureus).
› Verified 5 days ago
| Entity Name | Calcasieu Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215996467 PECOS PAC ID: 4183651425 Enrollment ID: O20050719000705 |
News Archive
A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells.
Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project' consortium to develop a vaccine against Staphylococcus aureus (S. aureus).
› Verified 5 days ago
| Entity Name | Congress Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912316944 PECOS PAC ID: 1557580354 Enrollment ID: O20140909002128 |
News Archive
A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells.
Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project' consortium to develop a vaccine against Staphylococcus aureus (S. aureus).
› Verified 5 days ago
| Entity Name | Sound Physicians Emergency Medicine Of Louisiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396253407 PECOS PAC ID: 1759642739 Enrollment ID: O20180308001149 |
News Archive
A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells.
Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project' consortium to develop a vaccine against Staphylococcus aureus (S. aureus).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Wall, MD 5539 W End Blvd # A, New Orleans, LA 70124-1848 Ph: () - | Dr Andrew Wall, MD 1 Medical Center Dr, Morgantown, WV 26506-1200 Ph: (304) 293-7215 |
News Archive
A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells.
Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project' consortium to develop a vaccine against Staphylococcus aureus (S. aureus).
› Verified 5 days ago
Dr. Nicole Lee Dorinzi, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Drive, Po 9149, Morgantown, WV 26506 Phone: 304-216-0980 | |
Kevin J Blankenship, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 63 Wharf St, Suite 100, Morgantown, WV 26501 Phone: 304-291-3627 Fax: 304-598-3630 | |
Dr. Joseph Michael Hartzog, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 710 Venture Dr, Morgantown, WV 26508 Phone: 304-291-5533 Fax: 304-291-5548 | |
Dr. Christopher Edwards, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 J D Anderson Dr, Morgantown, WV 26505 Phone: 304-598-1200 | |
Dr. John Harold Marsh, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 J D Anderson Dr, Emergency Department, Morgantown, WV 26505 Phone: 304-598-1200 | |
Matthew Kersteter, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Drive, Po 9149, Morgantown, WV 26506 Phone: 304-293-7215 Fax: 304-293-6702 | |
Dr. Jack F Ditty Iii, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 101 Stadium Drive, Morgantown, WV 26505 Phone: 304-598-4000 Fax: 304-293-6963 |